• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biogen Idec

Report: Biogen CEO eyes medical device market

July 23, 2018 By Sarah Faulkner

Biogen

After taking the helm at Biogen (NSDQ:BIIB) in 2016, Michel Vounatsos made use of acquisitions and geographic expansion to grow the company. Now, Vounatsos is reportedly considering another possible opportunity to differentiate the pharmaceutical player. The company’s chief executive hinted in an interview with Globes that Biogen could make a move into the medical technology space. “Up […]

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec

After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA

February 15, 2018 By Sarah Faulkner

Paratek's Omadacycline

More than two decades after it was first synthesized in a lab, omadacycline is finally being reviewed by the FDA for its potential as a broad-spectrum antibiotic. It’s a long-awaited milestone for Dr. Evan Loh, who serves as president, COO and CMO of Paratek Pharmaceuticals (NSDQ:PRTK), the company developing and commercializing omadacycline. It’s also emblematic of […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Hospital Care, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec, paratek

Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017

December 8, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, avitamedical, Bellerophon Therapeutics, biofilm, Biogen Idec, fractyllaboratories, novabay, Pediapharm, Tandem Diabetes Care

Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017

November 27, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Biogen Idec, Delcath Systems Inc., Eli Lilly & Co., Gamida Cell, Kala Pharmaceuticals, neurocrinebiosciences, pertinaxpharma, Pfizer Inc.

Earnings round-up: Biogen, Lilly & Novartis post Street-beating Q3 results

October 24, 2017 By Sarah Faulkner

Prescription drugs

When Johnson & Johnson posted its third quarter financial results last week, the healthcare giant credited its revenue growth to the strength of its pharmaceutical business. Three more pharmaceutical companies posted their Q3 results today, topping revenue and earnings estimates from analysts. Here’s a round-up of Q3 earnings from Biogen (NSDQ:BIIB), Eli Lilly (NYSE:LLY) and Novartis (NYSE:NVS). Biogen […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec, Eli Lilly & Co., Novartis

Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017

September 14, 2017 By Sarah Faulkner

Ocular Therapeutix

After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aeterna Zentaris, Bayer AG, Biogen Idec, Eyevensys, lyndra, Mylan, Ocular Therapeutix, Proteus Digital Health, rebiotix, Teva

Biotech, pharma chime in over Trump’s move to halt immigration program

September 6, 2017 By Sarah Faulkner

capitol hill

On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children. Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless […]

Filed Under: Featured, Legal News, Wall Street Beat Tagged With: Acorda Therapeutics, Alnylam Pharmaceuticals, Bigfoot Biomedical, Biogen Idec, decibeltherapeutics, junotherapeutics, ovidtherapeutics

House Dems launch MS drug pricing probe

August 17, 2017 By Sarah Faulkner

capitol hill

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of an investigation into why prices for multiple sclerosis drugs have nearly quadrupled since 2004. Reps. Elijah Cummings (D-Md.) and Peter Welch (D.-Mass) penned inquiries to Bayer (ETR:BAYN), Biogen (NSDQ:BIIB), EMD Serono, Novartis (NYSE:NVS), Roche (OTC:RHHBY), Sanofi Aventis (NYSE:SNY) and Teva Pharmaceuticals (NYSE:TEVA). […]

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Bayer AG, Biogen Idec, Capitol Hill, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

Biogen lifts outlook after strong Q2

July 25, 2017 By Sarah Faulkner

Biogen

Shares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results. The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec

Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017

July 13, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AstraZeneca plc, Avalon, Biogen Idec, cingulatetherapeutics, foamixpharmaceuticals, Gamida Cell, Ipsen, mannkind, milestonescientific, Novaliq GmbH, portal instruments

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS